Nektar Therapeutics (NKTR) Cash from Operations (2010 - 2026)

Nektar Therapeutics' Cash from Operations history runs 17 years deep, the most recent figure standing at 44298000.0 for Q1 2026.

• In Q1 2026, Cash from Operations rose 9.69% year-over-year to 44298000.0; the TTM figure through Mar 2026 stood at 203756000.0 (down 15.2% YoY), while the FY2025 annual figure was 208511000.0, down 18.67% from the prior year.
• Cash from Operations for Q1 2026 stood at 44298000.0, up from 64959000.0 in the prior quarter.
• The five-year high for Cash from Operations was 37702000.0 in Q2 2024, with the low at 88424000.0 in Q1 2022.
• The 5-year median for Cash from Operations is 48761000.0 (2025), against an average of 54419470.59.
• The sharpest annual moves came in 2022 and 2025: Cash from Operations surged 61.92% in 2022, then plunged 40.64% in 2025.
• Nektar Therapeutics' Cash from Operations stood at 57703000.0 in 2022, then climbed by 18.47% to 47047000.0 in 2023, then grew by 1.83% to 46187000.0 in 2024, then slumped by 40.64% to 64959000.0 in 2025, then soared by 31.81% to 44298000.0 in 2026.
• Business Quant data shows NKTR's Cash from Operations at 44298000.0 in Q1 2026, 64959000.0 in Q4 2025, and 48761000.0 in Q3 2025.